Bnt151, bnt411 und leider auch bnt 311/gen1046 wurden eingestellt:
While the emerging clinical profile of BNT311/GEN1046 (acasunlimab) is encouraging, for reasons relating to portfolio strategy, BioNTech opted not to participate in the further development of the program, including a planned Phase 3 trial. In the event that the program is commercialized, BioNTech will retain a tiered single-digit royalty on any potential sales. BioNTech and Genmab will continue their collaboration under the existing agreements which was expanded in 2022.
Nachlesen im q2 Bericht |